Eli Lilly

• GLP-1 drugs are driving higher sales for Eli Lilly and Novo Nordisk

  Sales of Mounjaro, Eli Lilly’s diabetes drug, rose 91 per cent in the second quarter of the year to US$9.94 billion, well above analysts' expectations.

  Health

  Aug 5
  
• ‘Hopeful milestone’: Health Canada approves 2nd drug to slow Alzheimer’s

  This is the second disease-slowing drug for Alzheimer’s that has been approved in Canada, after Health Canada approved lecanemab, commercially known as Leqembi, in October 2025.

  Canada

  May 4
  
• Advertisement
• FDA approves new Alzheimer’s drug that slows memory decline

  A key differentiating factor for donanemab is the drug's finite dosing, which allows patients to stop taking the treatment once brain scans no longer show amyloid plaques.

  Health

  Jul 3, 2024
• Advertisement
• Decision on Eli Lilly’s Alzheimer’s drug delayed by U.S. FDA

  The U.S. Food and Drug Administration has delayed its decision on Eli Lilly's LLY.N experimental treatment for early Alzheimer's disease.

  Health

  Mar 8, 2024
• Eli Lilly’s new version of diabetes drug Mounjaro approved for weight loss by FDA

  A new version of the popular diabetes treatment Mounjaro from Eli Lilly can be sold as a weight-loss drug, U.S. regulators announced Wednesday.

  Health

  Nov 8, 2023
• Alzheimer’s drug slows progression in patients. It may soon be approved in U.S.

  Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.

  Health

  Jul 17, 2023
• No insulin price cut coming for Canada despite U.S. slashes, Eli Lilly says

  Eli Lilly and Co. announced Wednesday that it will cut prices for some of its most commonly prescribed insulin products in the United States.

  Canada

  Mar 3, 2023
• Drugmaker Eli Lilly slashes prices, will offer $35 insulin in U.S. pharmacies

  In addition to slashing some drug prices by 70 per cent, Eli Lilly also promised to expand an existing program that caps some insulin products at $50.

  U.S. News

  Mar 1, 2023
• Advertisement
• FDA authorizes new antibody drug that targets Omicron COVID-19 variant

  The Food and Drug Administration said it cleared the Eli Lilly drug for adults and adolescent patients with mild-to-moderate cases of COVID-19.

  World

  Feb 11, 2022
• Advertisement
• U.S. limits use of Regeneron, Eli Lilly COVID-19 antibody treatments amid Omicron spread

  Last month, the U.S. had paused the distribution of Regeneron and Lilly's treatments and said the halt would continue until new data emerges on their efficacy against Omicron.

  Health

  Jan 24, 2022